Transient and mostly mild-to-moderate gastrointestinal symptoms were the most frequently reported AE and occurred more frequently with the 4 mg starting dose groups rather than the 2 mg starting dose groups [67]
If youre a payer, employer or provider navigating the GLP-1 revolution, dont rely solely on published trials
Semaglutide remains in the body for several weeks after the last dose, and animal studies showed potential fetal risks
This data suggests that more healthcare providers are seeing the benefits of these medications for treating obesity, which is a significant public health shift, Yee Hui Yeo, MD, a clinical fellow in the Karsh Division of Gastroenterology and Hepatology at Cedars-Sinai and co-first author of the study said in a press release
Even though the risk of thyroid cancer with the use of GLP-1 agonists is small, lets assume for a minute that it is large
Frequently asked questions (FAQs) What does GLP-1 do